As of 2026-10-02, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is -0.26 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.91 CAD, the upside of Helix Biopharma Corp is -128.34%.
Based on its market price of 0.91 CAD and our intrinsic valuation, Helix Biopharma Corp (HBP.TO) is overvalued by 128.34%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.26 - -0.26 | -0.26 | -128.34% |
| P/E | (0.05) - (0.10) | (0.08) | -108.3% |
| DDM - Stable | (0.32) - (2.33) | (1.32) | -245.4% |
| DDM - Multi | (0.47) - (2.78) | (0.82) | -189.9% |
| Market Cap (mil) | 86.14 |
| Beta | 3.53 |
| Outstanding shares (mil) | 94.66 |
| Enterprise Value (mil) | 83.66 |
| Market risk premium | 5.10% |
| Cost of Equity | 8.52% |
| Cost of Debt | 5.00% |
| WACC | 8.51% |